Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Saliba

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Cytotherapy|August 27, 2002
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantationI F Khouri, M J Keating, R M Saliba, et al.
American Journal of Epidemiology|October 8, 1999
Incidence of neonatal seizures in Harris County, Texas, 1992-1994R M Saliba, J F Annegers, D K Waller, et al.
American Journal of Epidemiology|June 28, 2001
Risk factors for neonatal seizures: a population-based study, Harris County, Texas, 1992-1994R M Saliba, F J Annegers, D K Waller, et al.
Bone Marrow Transplantation|February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokineticsI F Khouri, M Albitar, R M Saliba, et al.
Bone Marrow Transplantation|June 11, 2003
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancerR Wong, G Rondon, R M Saliba, et al.
Bone Marrow Transplantation|March 9, 2011
Prognostic value of response after upfront therapy for acute GVHDR M Saliba, D R Couriel, S Giralt, et al.
Bone Marrow Transplantation|June 26, 2007
Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantationE Gurkan, P A Patah, R M Saliba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphomaC Hosing, R M Saliba, P McLaughlin, et al.
Bone Marrow Transplantation|June 7, 2005
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemiaC Hosing, R M Saliba, M Shahjahan, et al.
Bone Marrow Transplantation|July 5, 2006
Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapyH J Lee, B Oran, R M Saliba, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Cytotherapy|August 27, 2002
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantationI F Khouri, M J Keating, R M Saliba, et al.
American Journal of Epidemiology|October 8, 1999
Incidence of neonatal seizures in Harris County, Texas, 1992-1994R M Saliba, J F Annegers, D K Waller, et al.
American Journal of Epidemiology|June 28, 2001
Risk factors for neonatal seizures: a population-based study, Harris County, Texas, 1992-1994R M Saliba, F J Annegers, D K Waller, et al.
Bone Marrow Transplantation|February 3, 2004
Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokineticsI F Khouri, M Albitar, R M Saliba, et al.
Bone Marrow Transplantation|June 11, 2003
Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancerR Wong, G Rondon, R M Saliba, et al.
Bone Marrow Transplantation|March 9, 2011
Prognostic value of response after upfront therapy for acute GVHDR M Saliba, D R Couriel, S Giralt, et al.
Bone Marrow Transplantation|June 26, 2007
Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantationE Gurkan, P A Patah, R M Saliba, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphomaC Hosing, R M Saliba, P McLaughlin, et al.
Bone Marrow Transplantation|June 7, 2005
Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemiaC Hosing, R M Saliba, M Shahjahan, et al.
Bone Marrow Transplantation|July 5, 2006
Steroid myopathy in patients with acute graft-versus-host disease treated with high-dose steroid therapyH J Lee, B Oran, R M Saliba, et al.
Pageof 3